CA
NZ
UK
AU
IND
US
Theriva Biologics, Inc. reported a net loss of $5.3 million for the quarter ended June 30, 2026, alongside cash and cash equivalents of $11.3 million. This is critical for investors assessing the company's financial flexibility as it advances its clinical programs.Key HighlightsNet loss narrowed …
Vireo Growth Inc. reported anEarnings Per Share(EPS) of $0.00 for the second quarter ending June 30, showing the company's ongoing strategic realignment amid aMergerplan with Planet 13 Holdings. This stagnation in earnings, alongside a volatile share performance, may concern investors looking for growth.Key HighlightsVireo …
Xtant Medical Holdings, Inc. has revised its 2026Revenueguidance down to a range of $99 million to $103 million, a decrease from a previous outlook of $101 million to $105 million. This adjustment highlights ongoing operational challenges, which could raise concerns for investors.Key HighlightsCut for …
Focus on Innovation as Growth Driver
Ultragenyx Pharmaceutical Inc. settled aPatentdispute with Esjay Pharma, allowing a generic version of DOJOLVI to launch in 2033. This strategic move opens market avenues but raises concerns for investors about competitive pricing pressure.Key HighlightsShares up 13.6% year-to-date but down 19.3% in the past month.Short …
Harvard Bioscience saw aRevenueincrease of 11% to $22.7 million for the second quarter, surpassing the consensus estimate. The upward revision of its full-year guidance to 3%-5% growth underscores strengtheningDemandand operational momentum, appealing to investors seeking stability.Key HighlightsQ2 adjusted EBITDA rose to $1.7 million from …
Kalaris Therapeutics, Inc. recorded a net loss of $11.5 million for the quarter ending June 30, 2026, compared with a loss of $11.4 million a year prior. This ongoing financial strain may heighten investor concerns regarding the company'sCapitalreserves and operational viability into late 2027.Key …
The revision arrives as investors watch the burgeoning demand for weight‑loss treatments and reassess exposure to companies positioned to capture that growth. By linking the upgrade to Lilly’s international strength, the bank underscores the importance of geographicDiversificationfor pharmaceutical players. The sector may see heightened …
Mereo BioPharma recorded a $7 million net loss for the second quarter of 2026. This financial outcome, while in line with expectations, raises investor concerns as shares drop 32.3% year-to-date, even amidst significant operational partnerships.Key HighlightsMereo's cash position, at $30.1 million, ensures operations into …
Prelude Therapeutics Inc reported a narrowed net loss of $13.9 million for the quarter ended June 30, 2026. The company's projected cash runway of $155 million is vital for funding ongoing oncology trials, making it a key focus for investors.Key HighlightsPrelude's shares have gained …
Please wait processing your request...